sales for Biogen’s multiple sclerosis (MS) franchise—which includes drugs like Tysabri and Tecfidera—declined 9% at constant currencies to a little more than $1 billion. For all of 2024 ...

Injectable medications for multiple sclerosis (MS) are known as disease-modifying therapies (DMTs). This means they work by slowing or changing the progression of the condition. These are self ...

Patients with relapsing-remitting multiple sclerosis (RRMS ... The decision means that Vumerity (diroximel fumarate) – a follow-up to Biogen's older oral therapy Tecfidera (dimethyl fumarate ...

Total revenue rose about 3% to $2.46 billion. Analysts had expected fourth-quarter sales of $2.41 billion. Overall sales of its multiple sclerosis drugs, which includes treatments such as Tecfidera ...

Botulinum toxin type A (BoNT-A), commonly known as Botox, has emerged as a promising option for managing multiple sclerosis (MS) symptoms. It may help reduce muscle contractions and spasms ...

There’s no single test that can diagnose multiple sclerosis. Instead, a diagnosis typically requires multiple tests to rule out other conditions with similar symptoms. Multiple sclerosis (MS ...

But sales of the core multiple-sclerosis portfolio fell 7% to $1.070 ... tysabri biosimilar in the U.S. and generic competition for tecfidera in Europe, he said. Each of them is a disease ...

Biogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to its blockbuster Tecfidera that promises to be less likely to cause gastrointestinal ...